DEFECTS OF THE RESPIRATORY CHAIN
(a) complex I deficiency (b) complex II deficiency (?) (c) complex III deficiency (d) complex IV deficiency (e) complex V deficiency (f) combined defects of respiratory chain components.
described at this meeting in fibroblasts from a patient with riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency (Rhead and Roettger, 1986) .
In the second case of non-thyroidal hypermetabolism (Luft disease), we found an abnormality in calcium transport of isolated muscle mitochondria . The rate of calcium uptake was normal, but calcium could not be retained within the mitochondria and was spontaneously released. Vicious cycling of calcium between mitochondria and cytosol might explain 'loose coupling' which is the biochemical hallmark of the disease, but the molecular abnormality is not known.
Carnitine patmitoyl transferase deficiency has been classified as a defect of substrate utilization (Clark et al., 1984; DiMauro et al., 1985) but it seems more appropriate to consider it among the defects of substrate transport (MorganHughes, 1986 ) because the role of carnitine palmitoyl transferase, in association with carnitine and the carnitine-acylcarnitine translocase, is to allow the translocation of long-chain fatty acids across the inner mitochondrial membrane into the matrix, where they can undergo ~-oxidation. Because oxidation of long-chain fatty acid is the main source of energy for prolonged exercise, particularly in fasting conditions, the clinical hallmark of carnitine palmitoyl transferase deficiency is myoglobinuria, usually precipitated by prolonged exercise, fasting or both (DiMauro and Papadimitriou, 1986b) . The disease is transmitted as an autosomal recessive trait with marked predominance of affected males. Although the enzyme defect seems to be generalized, symptoms and signs are confined to skeletal muscle. However, liver dysfunction has been described in some infants presenting with recurrent hypoglycaemia and encephalopathy (Bougneres et al., 1981) , a syndrome 115 reminiscent of systemic carnitine deficiency. The presence of varying amounts of residual carnitine palmitoyl transferase activity in muscle biopsies from different patients has stimulated investigations attempting to clarify whether carnitine palmitoyl transferase I and II (one bound to the outer, the other to the inner face of the inner mitochondrial membrane) were equally decreased. However, it may be impossible to discriminate the two activities in frozen muscle biopsies and the very existence of recognizable carnitine palmitoyl transferase I and II in heart and skeletal muscle has been questioned (Zierz and Engel, 1986) . Furthermore, it has been shown that the mutant enzyme is abnormally inhibited by increasing substrate/ product concentrations (Zierz and Engel, 1985; Mousson et al., 1986; Servidei and DiMauro, unpublished observations) . These abnormal kinetic properties would render the mutant enzyme least active when fatty acid metabolism is stressed, thus explaining the intermittent symptomatology and the modest accumulation of lipid droplets in muscle.
Carnitine deficiency
Primary myopathic carnitine deficiency can also be classified among the defects of substrate transport. The impaired translocation of long-and medium-chain fatty acids into the mitochondria results in massive triglyceride storage in the cytoplasm, which is the morphological hallmark of the disease (Engel, 1986) . Myopathic limb and trunk weakness usually starts in childhood and may fluctuate in severity. Carnitine concentration is decreased in muscle but normal in serum and liver. A defect of the active transport system of carnitine into the muscle cell has been documented in one patient by kinetic compartmental analysis (Rebouche and Engel, 1984) but the molecular defect remains to be demonstrated.
Systemic carnitine deficiency probably does not exist as a primary condition. Carnitine biosynthesis was normal in all patients examined and excessive renal 'leakage' of carnitine, demonstrated in several patients, could not be the only cause of the defect because it was also seen in at least one control (Enget et al., 1981) . Systemic carnitine deficiency can be secondary to other disorders causing excessive carnitine loss (renal Fanconi syndrome; chronic renal failure treated by haemodialysis) or decreased hepatic synthesis and dietary intake (cirrhosis with cachexia; kwashiorkor; total parenteral nutrition in premature infants), or it can be secondary to genetic defects of intermediary metabolism, such as organic acidurias, defects of B-oxidation and defects of the respiratory chain (Engel, 1986) . The mechanism of carnitine depletion in metabolic disorders appears to be mediated through excessive accumulation of acyl-CoAs. These compounds, which are toxic, are esterified to acylcarnitines and excreted in the urine, resulting in a net loss of carnitine. Irrespective of the primary defect, systemic carnitine deficiency is characterized clinically by recurrent hepatic encephalopathy of childhood, usually triggered by intercurrent illnesses, heralded by vomiting and followed by stupor, lethargy and coma. Carnitine replacement therapy is effective in many but not all patients with carnitine deficiency syndromes. Some patients with myopathic carnitine deficiency, who do not respond to carnitine supplementation, may improve dramatically with prednisone (Engel, 1986) .
DEFECTS OF SUBSTRATE UTILIZATION
Alterations of pyruvate metabolism may be due to defects of pyruvate carboxylase or the pyruvate dehydrogenase complex.
Pyruvate carboxylase deficiency is associated with failure to thrive, developmental retardation, seizures, and generalized hypotonia (DeVivo and Uziel, 1983) . Pyruvate carboxylase deficiency was also reported in four infants with the characteristic neuropathological lesions of Leigh's syndrome, but the enzyme defect was not documented unequivocally (Murphy et al., 1981; DeVivo and Uziel, 1983) .
The pyruvate dehydrogenase complex is composed of five enzymes, two of which, a kinase and a phosphatase, regulate the activity of the complex by phosphorylation (deactivation) and dephosphorylation (activation) of the first enzyme component (El). Syndromes of varying severity are associated with pyruvate dehydrogenase complex deficiency, from intermittent ataxia to congenital lactic acidosis, failure to thrive, developmental delay, generalized hypotonia and death in infancy (DeVivo and Uziel, 1983; Stansbie et al., 1986) . Specific defects of each component enzyme (El, E2, E3) have been documented (Stansbie et al., 1986) but the type and severity of symptoms seem to depend more on the amount of residual activity than on the enzyme involved.
Defects of [3-oxidation may affect muscle exclusively or in conjunction with other tissues. Glutaric aciduria type II (multiple acyl-CoA dehydrogenase deficiency) usually causes respiratory distress, hypoglycaemia, hyperammonaemia, systemic carnitine deficiency and non-ketotic metabolic acidosis in the neonatal period, with death within the first week. However, a few patients with onset in childhood or adult life showed lipid storage myopathy with weakness or premature fatigue ).
Short-chain acyl-CoA dehydrogenase deficiency was described in a 46-year-old woman with proximal limb weakness and exercise intolerance (Turnbull et al., 1984) . Muscle biopsy showed marked accumulation of lipid droplets. Although no other tissues were studied, the defect appeared to be confined to skeletal muscle, suggesting the existence of tissue-specific isozymes.
DEFECTS OF THE KREBS CYCLE
Fumarase deficiency was reported recently in an infant with mitochondrial encephalomyopathy (Zinn et al., 1986) . The defect cannot be very rare because two more cases have been presented at this meeting (Stacey et al., 1986; Christensen et al., 1986) . Two of these children had developmental delay since early infancy, microcephaly, hypotonia and cerebral atrophy; one died at 8 months of age. The third patient was a 3½-year-old mentally retarded girl. The laboratory hallmark of the disease is the excretion of large amounts of fumaric acid and, to a lesser extent, succinic acid in the urine. The enzyme defect, which involves both mitochondrial and cytosolic fumarase, was documented in muscle and liver biopsies from one patient (Zinn et al., 1986) and in cultured skin fibroblasts from the other two. Prenatal diagnosis may be possible in this severe neonatal encephalomyopathy (Stacey et al., 1986) . Morphologically, the muscle biopsy showed only non-specific changes by light microscopy, while electron miscroscopy showed an increased number of mitochondria (Zinn et al., 1986) .
The only other known defect of the Krebs cycle involves dihydrolipoyl dehydrogenase, a component of both pyruvate dehydrogenase complex and of the aketoglutarate dehydrogenase complex (Robinson et aI., 1977) . Although the clinical picture in this patient was characterized by encephalopathy with congenital lactic acidosis, the double enzyme defect was documented in multiple tissues including skeletal muscle (Robinson et aI., 1977) . As predicted by Zinn and colleagues (1986) , it is likely that other defects of the Krebs cycle will be identified in the near future as causes of infantile encephalomyopathy.
DEFECTS OF OXIDATION-PHOSPHORYLATION COUPLING
The best example of a disorder of oxidation-phosphorylation coupling is Luft disease, or non-thyroidal hypermetabolism. Only two patients with this condition have been reported, both women, one from Sweden and the other from Jordan (Luft et al., 1962; DiMauro et al., 1976) . Family history was non-contributory in both cases. Symptoms started in childhood or early adolescence with fever, heat intolerance, profuse perspiration, resting tachypnoea and dyspnoea, potydipsia, and polyphagia. At age 39, the Swedish patient was moderately weak, while the Jordanian patient had only mild weakness at age 22. The basal metabolic rate was markedly increased in both patients but all tests of thyroid function were normal. Muscle biopsies showed ragged-red fibres and proliferation of capillaries. Electron microscopy showed accumulations of mitochondria, some of which were greatly enlarged and contained abundant, tightly packed cristae and paracrystalIine or osmiophilic inclusions. Other tissues were morphologically normal. Studies of oxidative phosphorylation in isolated muscle mitochondria from both patients showed maximal respiratory rate even in the absence of ADP, an indication that respiratory control was lost. Respiration proceeded at a high rate, independent of phosphorylation, and energy was wasted as heat, causing hypermetabotism and hyperthermia. This condition, in which respiratory control is lost but phosphorylative efficiency is preserved, is called 'loose coupling'. As mentioned above, studies of calcium transport by isolated muscle mitochondria in the Jordanian patient suggested vicious cycling of calcium between mitochondria and cytosol. This might have caused sustained stimulation of respiration and loose coupling in vivo, but the molecular abnormality remains unknown, tn a recent review of this disorder, Ernster (1986) suggested the intiiguing possibility that muscle mitochondria from patients with Luft syndrome may contain an alien uncoupling protein, or 'thermogenin', normally found only in brown adipose tissue.
5, DEFECTS OF THE RESPIRATORY CHAIN
The respiratory chain is divided into five functional units or complexes, embedded in the inner mitochondrial membrane (Hatefi, 1985) . Complex I (NADH -coenzyme Q reductase) transports hydrogen from NADH to coenzyme Q and consists of 25 polypeptides, six of which are encoded by mitochondrial DNA (mtDNA). The prosthetic group is composed of flavin mononucleotide and six or seven nonhaem iron sulphur centres. Complex II (succinate -coenzyme Q reductase) contains four or five polypeptides, including the flavin adenine dinucleotide-dependent enzyme, succinate dehydrogenase, and a few non-haem iron sulphur centres. This is the only complex that does not contain any mtDNA-encoded protein. Complex III (reduced coenzyme Q -cytochrome c reductase) transports electrons from coenzyme Q to cytochrome c. It contains 9 or 10 proteins, one of which (the apoprotein of cytochrome b) is encoded by mtDNA. Complex IV (cytochrome c oxidase) is composed of two cytochromes (a and a3) , two copper atoms, and thirteen protein subunits, three of which are encoded by mtDNA. Complex V, or mitochondrial ATPase, consists of 12 to 14 subunits, of which two are encoded by mtDNA. Coenzyme Q and cytochrome c act as 'shuttles' between complexes. Cytochrome c is a low-molecular-weight haemoprotein; coenzyme Q is a lipoidal quinone.
Defects of complex I
Defects of complex I have been described in about 25 patients and seem to cause two major clinical syndromes (Table 2) : pure myopathy, with exercise intolerance and myalgia presenting in childhood or adult life (Arts et al., 1983 , MorganHughes et al., 1985 , or multisystem disorder. Patients with the multisystem disorder are not clinically homogeneous: some had a fatal infantile form of the disease causing severe congenital lactic acidosis, hypotonia, seizures, respiratory insufficiency and death before 3 months of age (Moreadith et aI., 1984; Robinson et al., 1986a and b) . Others had a less severe encephalomyopathy with onset in childhood or adult life and characterized by the association, in various proportions, of the following symptoms and signs: exercise intolerance, weakness, ophthalmoplegia, pigmentary degeneration of the retina, optic atrophy, sensorineurat hearing loss, dementia, cerebellar ataxia, pyramidal signs (Morgan-Hughes et al., 1985; Turnbull et aL, 1986) . Defects of complex I have been reported in at least one patient with a special form of encephalomyopathy, known as MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) . A defect of NADH-CoQ reductase was suggested by biochemical studies of pyruvate oxidation in liver and muscle from a child with the clinical and neuropathological features of progressive infantile poliodystrophy or Alper's disease (Prick et al., 1981) .
This clinical heterogeneity is hardly surprising when one considers the large number of proteins that compose complex I, but the molecular defect in most patients is not known. It is also likely that one or more of the subunits may be tissue-specific to explain the exclusive involvement of skeletal muscle in some patients, but this remains to be documented. In an infant with fatal infantile generalized complex I deficiency, the biochemical defect was further localized between FMN and CoQ, and electron paramagnetic resonance (EPR) spectroscopy of liver submitochondrial particles pinpointed the lesion to an almost complete absence of the iron-sulphur clusters characteristic of complex I, while the ironsulphur clusters of complex II and III were normal (Moreadith et al., 1984) . Further immunological studies using antibodies against the holoenzyme or against the four main subunits of the iron-protein fragment of complex I showed selective absence of two polypeptides (MW75 kDa and 13 kDa) (Moreadith et al., 1987) . Therapy with oral riboflavin (100mg daily) was beneficial in one patient with myopathy (Arts et al., 1983) .
Defects of complex II
In the few reported patients with complex II deficiency, the biochemical defect has not been fully characterized, and the diagnosis has often been based solely on a decrease of succinate-cytochrome c reductase activity (Sengers et al., 1983; Behbehani et al., 1984; Riggs et al., 1984; Sperl et al., 1986) .
The clinical picture was characterized by severe infantile myopathy with lactic acidosis in two cases (Sengers et al., 1983; Behbehani et aI., 1984) and by encephalomyopathy in three others (Riggs et al., 1984; Sperl et al., 1986) . The finding of increased urinary excretion of succinate, malate and fumarate in the patient of Behbehani and colleagues (1984) raises the possibility of a defect in the Krebs cycle, despite the markedly decreased activity of succinate-cytochrome c reductase in muscle.
Defects of complex III
Complex III deficiency has been documented in 13 patients, nine of whom were studied by Morgan-Hughes and co-workers (Morgan-Hughes et al., 1985) . As in defects of complex I, the clinical picture falls into one of two groups (Table 2 ):
1. Myopathy with onset in childhood or adolescence was seen in nine patients, four of whom had involvement of extraocular muscles (Morgan-Hughes et aI., 1985; Kennaway et al., 1984; Reichman et aI., 1986) . 2. The other 5 patients had a multisystem disorder (encephalomyopathy) with exercise intolerance, fixed weakness, pigmentary degeneration of the retina, sensorineural hearing loss, cerebellar ataxia, pyramidal signs, dementia (Spiro et al., 1970; Morgan-Hughes et aI., 1985) Biochemically, five patients showed lack of reducible cytochrome b (Spiro et al., 1970; Kennaway et al., 1984; Morgan-Hughes et al., 1985) , one had a combined deficiency of cytochrome b and ca (Hayes et al., 1984) , and seven had normal cytochrome spectra (Morgan-Hughes et al., 1985; Reichmann et al., 1986) . In the patients with a normal amount of reducible cytochrome b, the defect may involve the non-haeme iron sulphur protein (Rieske protein) or coenzyme Q. Immunological studies showed that antibodies against complex III purified from beef heart crossreacted with four subunits of human muscle complex III, representing core protein 1 and 2, peptide VI, and cytochrome cl (Darley-Usmar et at., 1983 ). In the patient described by Kennaway et al. (1984) , immunostaining of the core protein and of peptide VI was markedly decreased, whereas the band of cytochrome cl stained normally. In this same patient, the bioenergetic capacity of muscle was also studied by 31p magnetic resonance (NMR) (Eleff et al., 1984) . The ratio of phosphocreatine to inorganic phosphate concentration was greatly reduced at rest, decreased further with mild exercise, and returned to pre-exercise values very slowly. Because the site of the block in the respiratory chain was known, menadione (vitamin K3) and ascorbate (vitamin C), two compounds whose redox potentials 'fit' the gap between Co-enzyme Q and cytochrome c, were administered orally. There was marked improvement of exercise capacity and NMR showed increased phosphocreatine:inorganic phosphate ratios at rest as well as improved rates of recovery after exercise. The improvement appeared to be sustained as shown by both clinical and NMR criteria in a one-year follow-up study (Argov et al., 1986) .
The existence of tissue-specific isozymes of complex III is suggested by two complementary observations. Firstly, in a patient with myopathy only , the complex appeared normal in cultured fibroblasts and transformed lymphoid cells (Darley-Usmar et al., 1986) . Conversely, in a patient with histiocytoid cardiomyopathy of infancy, complex III activity and the amount of reducible cytochrome b were markedly decreased in cardiac muscle, while the activity was normal in skeletal muscle and liver .
Defects of complex IV
As seen with defects of complex I and complex III, the clinical phenotypes of complex IV (cytochrome oxidase) deficiency fall into two main groups, one in which myopathy is the predominant or exclusive manifestation, another in which brain dysfunction predominates (Table 2 ).
In the first group, the most common disorder is fatal infantile myopathy causing generalized weakness, respiratory insufficiency, and death before age 1 year . There is lactic acidosis and, often, renal dysfunction with glycosuria, phosphaturia and aminoaciduria (DeToni-Fanconi-Debre syndrome). The association of myopathy and cardiopathy in the same patient (Zeviani et al., 1986b) and myopathy and liver disease (Boustany et at., 1983) in the same family (but not in the same patient) has also been described.
In patients with pure myopathy, cytochrome oxidase deficiency is confined to skeletal muscle, sparing heart, liver, and brain (Bresolin et al., 1985) . A partial enzyme defect in kidney was shown in patients with myopathy and renal dysfunction (DiMauro et al., 1980; Minchom et al., 1983) , and both muscle and cardiac cytochrome oxidase activities were decreased in a child with myopathy and cardiopathy (Zeviani et al., 1986b) . In patients with fatal infantile myopathy, the amount of immunologically reactive enzyme protein was markedly decreased in muscle extracts or isolated mitochondria when tested in an enzyme-linked immunosorbent assay (ELISA) or by immunocytochemistry of frozen sections (Bresolin et al., 1985; Zeviani et al., 1985) . The subunit composition of the mutant cytochrome oxidase was studied by immunoprecipitation of muscle mitochondrial extracts followed by SDS-PAGE of the immunoprecipitate: no alteration of cytochrome oxidase subunit composition was found in one patient (Bresolin et al., 1985) .
In contrast to these invariably fatal conditions, a few children with severe myopathy and lactic acidosis at birth improve spontaneously and are virtually normal by age 2 or 3 years. Serum lactate and muscle biopsy also return to normal in this benign infantile mitochondriat myopathy , which is due to a reversible cytochrome oxidase deficiency. The enzyme activity is markedly decreased (tess than 10% of normal) in muscle biopsies taken soon after birth, but returns to normal in the first year of life. Immunocytochemistry and immunotitration showed normal amount of enzyme protein in all muscle biopsies, including the initial ones with very low activity . This contrasts with the virtual lack of immunologically cross-reacting material (CRM) in patients with fatal infantile myopathy, and may represent a useful prognostic test.
The selective involvement of one or more tissues and the reversibility of the muscle defect in the benign form suggest the existence of tissue-specific and developmentally regulated cytochrome oxidase isozymes in humans, in agreement with data obtained in rat tissues i985) . A mutation affecting a foetal or neonatal isozyme of muscle cytochrome oxidase, but not the adult isoform, could explain the transient expression of cytochrome oxidase deficiency in the neonatal period . Alternatively, the reversibility of cytochrome oxidase deficiency could be due to a mutation of mtDNA: fibres containing predominantly mutant mitochondria would be cytochrome oxidase deficient and presumably not viable. The 'return' of the enzyme could be ascribed to a gradual selection of fibres containing predominantly wildtype mitochondria (DiMauro et aI., 1986a) .
Of the second group of disorders, dominated by involvement of the central nervous system, subacute necrotizing encephalomyelopathy (SNE, Leigh's syndrome) appears to be the most common. Leigh's syndrome usually starts in infancy or childhood, and is characterized by psychomotor retardation, brainstem abnormalities and seizures. The pathological hallmark consists of focal, symmetrical necrotic lesions extending from thalamus to pons and involving the inferior olives and the posterior columns of the spinal cord. Microscopically, these 'spongiform' lesions show demyelination, vascular proliferation and astrocytosis. Cytochrome oxidase deficiency has been reported in four patients with neuropathologically documented Leigh's syndrome Miyabayashi et al., 1983; Hoganson et al., 1984) , and we have recently studied five more . The defect appears to be generalized, including cultured fibroblasts in most (but not all) patients: this may provide a useful tool for prenatal diagnosis in at least some families. Immunological studies show the presence of CRM in all tissue . Partial defects of cytochrome oxidase have been reported in patients with progressive external ophthalmoplegia and proximal myopathy Byrne et al., 1985) and in patients with encephalomyopathy (Pezeshkpour et al., 1984; Servidei et al., 1987) , but the precise pathogenic significance of cytochrome oxidase deficiency in these disorders remains uncertain.
The clinical and biochemical heterogeneity of cytochrome oxidase deficiency suggests that different genetic defects are involved. To elucidate these defects at the molecular level, we are trying to obtain cDNA clones for all nuclearly coded subunits of human cytochrome oxidase . Using these nuclear genes as probes, we plan to examine tissues from patients with different phenotypes of cytochrome oxidase deficiency by Southern and Northern analysis in conjunction with in situ hybridization techniques.
Defects of complex V (ATPase) Two patients with muscle mitochondrial ATPase deficiency have been reported. One was a young woman with congenital, slowly progressive myopathy. At age 37, she could walk but had difficulty climbing stairs. Muscle biopsy showed ragged-red fibres and electron microscopy showed that most mitochondria contained paracrystalline inclusions. Respiration of isolated mitochondria was decreased with all substrates but returned to normal after addition of the uncoupling agent 1,4-dinitrophenol, suggesting that the limiting step involved the 123 phosphorylative pathway rather than the respiratory chain. ATPase activity was decreased and responded poorly to dinitrophenol stimulation.
The second patient (Clark et aI., 1983 (Clark et aI., , 1984 ) was a 17-year-old boy who, at age 10, was found to have muscle carnitine deficiency (Smyth et aI., 1975) but went on to develop a multisystem disorder characterized by weakness, dementia, ataxia, retinopathy and peripheral neuropathy. Also in this patient the biochemical clue to a defect of ATPase was that the rate of respiration of isolated muscle mitochondria was depressed with all substrates but increased markedly by addition of uncouplers or calcium ions.
Combined defects Combined defects of respiratory chain components have also been described. Many patients with fatal infantile myopathy due to cytochrome oxidase deficiency also had partial defects of cytochrome b (Van Biervtiet et at., 1977; DiMauro et al., 1980; Minchon et al., 1983; Muller-Hocker et al., 1983; Sengers et aI., 1984) , and one patient with complex III deficiency also lacked cytochrome ccl (Hayes et al., 1984) .
Tissues from one of the patients with combined defects of complex III and IV (Sengers et al., 1984) were studied recently in more detail (Takamiya et al., 1986) . Immunoblotting of muscle mitochondria with antibodies against complex III and complex IV showed that several components of complex III (core proteins I and II and non-haeme sulphur protein) were decreased, as were subunits MtII, ASA and STA (II, Via and VIc in Kadenbach's nomenclature) of complex IV. Because complex III and complex IV appear to be linked only at the level of mtDNA translation and processing of the polycrystronic mRNA, it has been suggested that the defect in this child might involve a nuclearly encoded protein controlling these events (Takamiya et al., 1986) .
CONCLUSIONS
The veritable explosion of biochemical studies in patients with mitochondrial myopathies or encephalomyopathies in recent years is making possible a rational classification of these clinically heterogeneous disorders. However, the biochemical defect is still elusive in many patients with morphologically defined mitochondrial myopathies. A tentative classification of these patients on the basis of clinical and genetic features has been proposed by 'splitters' (Rowland et al., 1983; Pavlakis et al., 1984; DiMauro et al., 1985) and questioned by 'lumpers' (Petty et al., 1985) , which only stresses the importance of continuing biochemical investigation.
Even biochemically defined disorders, such as defects of the respiratory chain, show striking clinical and biochemical heterogeneity, suggesting the need to go beyond the identification of the site of the lesion to a definition of the molecular defect. This type of investigation has already begun (Darley-Usmar et al., 1983; Moreadith et al., 1984; Bresotin et al., 1985) and promises to be very fruitful. Finally, molecular genetic studies are underway and will be facilitated by the fact that human mtDNA has been fully sequenced (Anderson et al., 1981) .
Studies of patients will not only clarify pathogenic mechanisms but will also contribute to'a better understanding of more basic biological phenomena, such as cytoplasmic heredity, the co-ordination between mitochondrial and nuclear gene expression, and the tissue specificity and developmental control of mitochondrial enzymes.
